How Biosense Webster aims to expand access to AFib care

Biosense Webster U.S. President Nikki Sidi [Image courtesy of Biosense Webster]

Electrophysiology is “an incredibly vibrant space,” said Nikki Sidi, but access remains a challenge.

Nikki Sidi, the U.S. president of Johnson & Johnson’s Biosense Webster, can look at her own company as one of those paving the way in electrophysiology (EP). Its recent milestones include multiple atrial fibrillation (AFib) mapping catheters, including ablation and mapping devices. 

Sidi has worked across a number of businesses at J&J, including leading U.S. marketing for Biosense Webster. She took on the post of U.S. president at Biosense Webster in December 2022 after a stint with J&J Vision. 

Her return to Biosense Webster — and her return to AFib treatments — has been nothing short of “amazing,“ she said in an interview. Biosense Webster competes in a market that also includes …

Read more
  • 0

Johnson & Johnson Medical Devices drops ‘medical devices’ in rebranding

Johnson & Johnson Medical Devices has rebranded as Johnson & Johnson MedTech as the unit moves deeper into digital technology.

New Brunswick, New Jersey-based Johnson & Johnson (NYSE: JNJ) noted the coming change in its 2022 annual report published last month, saying the switch would take effect in the company’s first fiscal quarter.

Johnson & Johnson MedTech EVP and Executive Chair Ashley McEvoy [Photo courtesy of Johnson & Johnson]That preview was followed by an announcement of approximately 100 words, mostly attributed to Johnson & Johnson MedTech EVP and Executive Chair Ashley McEvoy.

Johnson & Johnson provided more information to Medical Design & Outsourcing today.

Get the full story at our sister site, Medical Design & Outsourcing.

Read more
  • 0

Johnson & Johnson Medical Devices drops ‘medical devices’ in rebranding

Johnson & Johnson Medical Devices has rebranded as Johnson & Johnson MedTech as the unit moves deeper into digital technology.

New Brunswick, New Jersey-based Johnson & Johnson (NYSE: JNJ) noted the coming change in its 2022 annual report published last month, saying the switch would take effect in the company’s first fiscal quarter.

That preview was followed by a March 7 announcement of approximately 100 words, mostly attributed to Johnson & Johnson MedTech EVP and Executive Chair Ashley McEvoy.

Johnson & Johnson MedTech EVP and Executive Chair Ashley McEvoy [Photo courtesy of Johnson & Johnson]

“Our business sits at the compelling intersection of medical devices and medical technology, and as the world’s most broadly based medtech company, we are committed to delivering breakthrough scientific innovation and reimagining health in an increasingly digital world,”…
Read more
  • 0